Generic Name
Tirzepatide
Brand Names
Zepbound, Mounjaro
FDA approval date: May 13, 2022
Classification: GLP-1 Receptor Agonist
Form: Injection
What is Zepbound (Tirzepatide)?
ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea in adults with obesity. ZEPBOUND ® is a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea in adults with obesity. Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 receptor agonist is not recommended.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)
Summary: This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating ...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight
Summary: The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
Summary: The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly ...
Related Latest Advances
Brand Information
ZEPBOUND (tirzepatide)
WARNING: RISK OF THYROID C-CELL TUMORS
- In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined[see Warnings and Precautions (
- ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[see Contraindications (. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND[see Contraindications (
1INDICATIONS AND USAGE
ZEPBOUND
- to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
- to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
2DOSAGE FORMS AND STRENGTHS
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
3CONTRAINDICATIONS
ZEPBOUND is contraindicated in patients with:
- A personal or family history of MTC or in patients with MEN 2
- Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide
4ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information:
- Risk of Thyroid C-cell Tumors
- Severe Gastrointestinal Adverse Reactions
- Acute Kidney Injury Due to Volume Depletion
- Acute Gallbladder Disease
- Acute Pancreatitis
- Hypersensitivity Reactions
- Hypoglycemia
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus
- Pulmonary Aspiration During General Anesthesia or Deep Sedation
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
4.2Postmarketing Experience
The following adverse reactions have been reported during post-approval use of tirzepatide, the active ingredient in ZEPBOUND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.
Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction
Hypersensitivity: anaphylaxis, angioedema
Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.
Renal: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis
5OVERDOSAGE
In the event of an overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days.
6DESCRIPTION
ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C
Structural formula:
ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5.
Each single-patient-use KwikPen contains additional volume to allow for device priming.
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling
8PATIENT MEDICATION GUIDE
ZEP-0008-MG-20260225
9SINGLE-DOSE PEN INSTRUCTIONS FOR USE
Important information you need to know before injecting ZEPBOUND
Read this Instructions for Use and the Medication Guide before using your ZEPBOUND pen and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Talk to your healthcare provider about how to inject ZEPBOUND the right way.
- ZEPBOUND is a single-dose prefilled pen.
- ZEPBOUND is used 1 time each week.
- Inject under the skin (subcutaneously) only.
- You or another person can inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Guide to parts
Preparing to inject ZEPBOUND
Disposing of your used pen
- Put your used pen in an FDA-cleared sharps disposal container right away after use.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
- Do not recycle your used sharps disposal container.
Storage and handling
- Store your pen in the refrigerator between 36°F to 46°F (2°C to 8°C).
- You may store your pen at room temperature up to 86°F (30°C) for up to 21 days. If you store the pen at room temperature, do not return the pen to the refrigerator.
- Discard the pen if not used within 21 days after removing from the refrigerator.
- Do not freeze your pen. If the pen has been frozen, throw the pen away and use a new pen.
- Store your pen in the original carton to protect your pen from light.
- The pen has glass parts. Handle it carefully. If you drop the pen on a hard surface,
- Keep your ZEPBOUND pen and all medicines out of the reach of children.
Commonly asked questions
What if I see air bubbles in my pen?
Air bubbles are normal.
What if my pen is not at room temperature?
It is not necessary to warm the pen to room temperature.
What if I unlock the pen and press the purple injection button before pulling off the gray base cap?
Do not remove the gray base cap. Throw away the pen and get a new pen.
What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?
A drop of liquid on the tip of the needle is normal.
Do I need to hold the injection button down until the injection is complete?
This is not necessary, but it may help you keep the pen steady against your skin.
I heard more than 2 clicks during my injection—2 loud clicks and 1 soft one. Did I get my complete injection?
Some people may hear a soft click right before the second loud click. That is the normal operation of the pen.
I am not sure if my pen worked the right way.
What if there is a drop of liquid or blood on my skin after my injection?
This is normal. Press a cotton ball or gauze over the injection site.
Other information
- If you have vision problems,
Where to learn more
- If you have questions or problems with your ZEPBOUND pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.
- For more information about the ZEPBOUND pen, visit our website at www.zepbound.com.
Marketed by:
ZEPBOUND is a trademark of Eli Lilly and Company.
Copyright © 2023, Eli Lilly and Company. All rights reserved.
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: November 2023
ZEP-0002-PEN-IFU-20231109
10SINGLE-DOSE VIAL INSTRUCTIONS FOR USE
Important information you need to know before injecting ZEPBOUND
Read this Instructions for Use before you start taking ZEPBOUND and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.
Talk to your healthcare provider about how to inject ZEPBOUND the right way.
- ZEPBOUND is a single-dose vial.
- ZEPBOUND is used 1 time each week.
- Inject under the skin (subcutaneously) only.
- You or another person may inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Gather supplies needed to give your injection
- 1 single-dose ZEPBOUND vial
- 1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
- 1 alcohol swab
- gauze
- 1 sharps container for throwing away used needles and syringes.
Note: The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.
Preparing to inject ZEPBOUND
Remove the vial from the refrigerator.
Check the vial label to make sure you have the right medicine and dose, and that it has not expired.
Make sure the medicine:
Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.
Wash your hands with soap and water.
Injecting ZEPBOUND
- Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
- Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- Do not inject where the skin has pits, is thickened, or has lumps.
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
- Do not mix ZEPBOUND with any other medicine.
- Do not inject ZEPBOUND in the same injection site used for other medicines.
Disposing of used needles and syringes
- Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at:
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Storing ZEPBOUND
- Store all unopened vials in the refrigerator at 36°F to 46°F (2°C to 8°C).
- You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.
- Do not freeze. Do not use if ZEPBOUND has been frozen.
- Store the vial in the original carton to protect from light.
- Throw away all opened vials after use, even if there is medicine left in the vial.
Keep ZEPBOUND vials, syringes, needles, and all medicines out of the reach of children.
If you have any questions or problems with your ZEPBOUND, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
Marketed by:
ZEPBOUND is a registered trademark of Eli Lilly and Company.
Copyright © 2024, Eli Lilly and Company. All rights reserved.
ZEP-0001-VL-IFU-20240328
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Issued: March 2024
11MULTIPLE-DOSE VIAL INSTRUCTIONS FOR USE
INSTRUCTIONS FOR USE
ZEPBOUND
(tirzepatide)
injection, for subcutaneous use
Multi-dose vial
Each vial contains 4 doses, one dose taken weekly.
Important information you need to know before injecting ZEPBOUND
Read this Instructions for Use before you start taking ZEPBOUND and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your needles or syringes with other people.
Talk to your healthcare provider about how to inject ZEPBOUND the right way.
- ZEPBOUND is a multi-dose vial.
- Inject
- You or another person may inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Gather supplies needed to give your injection
- 1 multi-dose ZEPBOUND vial
- 1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
- 1 alcohol swab
- gauze
- 1 sharps container for throwing away used needles and syringes.
Note: The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.
Preparing to inject ZEPBOUND
Check the vial label to make sure you have the right medicine and dose, and that it has not expired.
Make sure the medicine:
Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.
Wash your hands with soap and water.
Injecting ZEPBOUND
- Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
- Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- Do not inject where the skin has pits, is thickened, or has lumps.
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
- Do not mix ZEPBOUND with any other medicine.
- Do not inject ZEPBOUND in the same injection site used for other medicines.
Disposing of used needles and syringes
- Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Storing ZEPBOUND
- Do not freeze. Do not use if ZEPBOUND has been frozen.
- Store ZEPBOUND in original carton. Keep away from light.
Unopened vial:
- Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C). It can be used until the expiration date on the label if kept in the refrigerator.
- If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.
After vial has been opened:
- Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)]. Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.
Keep ZEPBOUND vials, syringes, needles, and all medicines out of the reach of children.
If you have any questions or problems with your ZEPBOUND, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
Marketed by:
ZEPBOUND is a registered trademark of Eli Lilly and Company.
Copyright © 2026, Eli Lilly and Company. All rights reserved.
ZEP-0001-MDV-IFU-20260107
This Instructions for Use has been approved by the U.S. Food and Drug Administration .
Revised: January 2026
12MULTI-DOSE KWIKPEN INSTRUCTIONS FOR USE
INSTRUCTIONS FOR USE
ZEPBOUND®[ZEHP-bownd] KwikPen®[KWIHK pehn]
(tirzepatide)
injection, for subcutaneous use
multi-dose single-patient-use prefilled pen
Each pen contains 4 fixed doses, one dose taken weekly.
This Instructions for Use contains information on how to inject ZEPBOUND.
Read this
- ZEPBOUND KwikPen is a disposable multi-dose single-patient-use prefilled pen.
For your weekly dose, you need to turn the dose knob all the way until it stops AND the - After 4 doses, throw away (discard) the Pen, including the unused medicine. The Pen will prevent you from dialing a full dose after you have given yourself 4 weekly doses.
- Do not share your ZEPBOUND Pen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.
- People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.
Parts of the ZEPBOUND Pen
Unused Pens:
- Store
- Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.
- Do not freeze your Pen. Throw away (discard) the Pen if it has been frozen.
Used Pens:
- You may store your
- Keep away from heat and light.
- Keep your Pen and needles out of the sight and reach of children.
- Throw away the Pen 30 days after first use even though the Pen has medicine left in it.
- Throw away the Pen after receiving 4 weekly doses. Attempting to inject any leftover medicine could result in an incomplete dose even though the Pen still has medicine left in it.
- Put your used pen needles in an FDA-cleared sharps disposal container right away after use.
- Do not throw away (discard) loose pen needles in your household trash.
- Discard the used Pen in your household trash or FDA-cleared sharps disposal container after you have removed the needle.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away (discard) used needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
- If you cannot remove the Pen cap, gently twist the Pen cap back and forth, and then pull the Pen cap straight off.
- If the dose knob is hard to push:
If the Pen prevents you from turning the dose knob until the - Throw away (discard) the Pen, including the unused medicine. There may not be enough medicine left in the pen to give a full dose.
Additional Information:
If you have any questions or problems with ZEPBOUND KwikPen:
ZEPBOUND
Marketed by:
Copyright © 2026, Eli Lilly and Company. All rights reserved.
ZEPBOUND KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: January 2026
ZEPKP-0002-IFU-20260121
13PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 2.5 mg/0.5 mL Dose
NDC 0002-2506-80
Zepbound
(tirzepatide) injection
2.5 mg/0.5 mL
4 x 2.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
14PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 5 mg/0.5 mL Dose
NDC 0002-2495-80
Zepbound
(tirzepatide) injection
5 mg/0.5 mL
4 x 5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
15PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 7.5 mg/0.5 mL Dose
NDC 0002-2484-80
Zepbound
(tirzepatide) injection
7.5 mg/0.5 mL
4 x 7.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
16PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 10 mg/0.5 mL Dose
NDC 0002-2471-80
Zepbound
(tirzepatide) injection
10 mg/0.5 mL
4 x 10 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
17PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 12.5 mg/0.5 mL Dose
NDC 0002-2460-80
Zepbound
(tirzepatide) injection
12.5 mg/0.5 mL
4 x 12.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
18PACKAGE LABEL - Zepbound Prefilled Pen (Autoinjector) - 15 mg/0.5 mL Dose
NDC 0002-2457-80
Zepbound
(tirzepatide) injection
15 mg/0.5 mL
4 x 15 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Use one pen every week.
4 Single-dose prefilled pens
Lilly
19PACKAGE LABEL - Zepbound Single-Dose Vial - 2.5 mg/0.5 mL Dose
NDC 0002-0152-04
Zepbound
(tirzepatide) injection
2.5 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
20PACKAGE LABEL - Zepbound Single-Dose Vial - 5 mg/0.5 mL Dose
NDC 0002-0243-04
Zepbound
(tirzepatide) injection
5 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
21PACKAGE LABEL - Zepbound Single-Dose Vial - 7.5 mg/0.5 mL Dose
NDC 0002-1214-04
Zepbound
(tirzepatide) injection
7.5 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
22PACKAGE LABEL - Zepbound Single-Dose Vial - 10 mg/0.5 mL Dose
NDC 0002-1340-04
Zepbound
(tirzepatide) injection
10 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
23PACKAGE LABEL - Zepbound Single-Dose Vial - 12.5 mg/0.5 mL Dose
NDC 0002-1423-04
Zepbound
(tirzepatide) injection
12.5 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
24PACKAGE LABEL - Zepbound Single-Dose Vial - 15 mg/0.5 mL Dose
NDC 0002-2002-04
Zepbound
(tirzepatide) injection
15 mg/0.5 mL
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Use one vial every week.
4 Single-dose vials
Discard unused portion
Lilly
25PACKAGE LABEL - Zepbound Multi-Dose Vial - 2.5 mg/0.6 mL Dose (10 mg/2.4 mL [4.17 mg/mL])
Rx Only
NDC 0002-6052-11
Zepbound
(tirzepatide) injection
10 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 2.5 mg/0.6 mL Dose (10 mg/2.4 mL [4.17 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-2pt5mg-mdv-787132.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
26PACKAGE LABEL - Zepbound Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL])
Rx Only
NDC 0002-6103-11
Zepbound
(tirzepatide) injection
20 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-5mg-mdv-787133.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
27PACKAGE LABEL - Zepbound Multi-Dose Vial - 7.5 mg/0.6 mL Dose (30 mg/2.4 mL [12.5 mg/mL])
Rx Only
NDC 0002-6210-11
Zepbound
(tirzepatide) injection
30 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 7.5 mg/0.6 mL Dose (30 mg/2.4 mL [12.5 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-7pt5mg-mdv-787134.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
28PACKAGE LABEL - Zepbound Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL])
Rx Only
NDC 0002-6304-11
Zepbound
(tirzepatide) injection
40 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-10mg-mdv-787135.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
29PACKAGE LABEL - Zepbound Multi-Dose Vial - 12.5 mg/0.6 mL Dose (50 mg/2.4 mL [20.8 mg/mL])
Rx Only
NDC 0002-6523-11
Zepbound
(tirzepatide) injection
50 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 12.5 mg/0.6 mL Dose (50 mg/2.4 mL [20.8 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-12pt5mg-mdv-787136.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
30PACKAGE LABEL - Zepbound Multi-Dose Vial - 15 mg/0.6 mL Dose (60 mg/2.4 mL [25 mg/mL])
Rx Only
NDC 0002-6612-11
Zepbound
(tirzepatide) injection
60 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Zepbound Multi-Dose Vial - 15 mg/0.6 mL Dose (60 mg/2.4 mL [25 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zep-15mg-mdv-787137.jpg&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)